Alerion is a biotechnology company founded in 2016 and dedicated to the development and implementation of a new gene therapy vector platform for the treatment of severe inherited and acquired diseases.
Our gene therapy platform makes use of a novel integrating retroviral vector system for gene therapy based on the alpharetrovirus family. Unlike other integrating vector systems, alpharetroviral SIN vectors integrate in a near-random fashion into host cells, avoiding potentially harmful regions, such as promoter / enhancer regions and gene structures. To enable efficient and scalable manufacturing, we have developed stable human packaging cells to produce alpharetroviral SIN vectors.
Our gene therapy approach uses a patient's own cells (hematopoietic stem cells or immune effector cells) which are collected from the patient, modified to introduce the new gene copy using our alpharetroviral vectors, and re-introduced into the patient.
Our mission and vision is to develop innovative gene therapy technologies for the treatment of life-threatening diseases and to make gene therapy accessible to more patients. Our platform has applications in the correction of genetic disease (by providing a functional copy of the defective gene) and in cancer immunotherapy as an approach to engineering cell therapies such as CAR-T. Contact us to learn more.